Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
>
Tvardi Therapeutics’ stock crashes on Phase II IPF flop
Tvardi Therapeutics’ stock crashes on Phase II IPF flop
Read also
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
Teva Pharmaceutical Industries Limited recently announced that the FDA has approved expanded use of its branded product, Uzedy (risperidone).
FDA Breakthrough Designation Signals New Therapeutic Avenue in R/R MCL
The FDA has granted breakthrough therapy designation (BTD) to the investigational B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax (BGB-11417) for the treatment of adult patients...
Preclinical study identifies genetic misfire in lupus
Cedars-Sinai investigators have identified a "molecular switch" on a gene strongly associated with the autoimmune disease lupus, which appears to propel immune cells into overdrive, attackin...
Preclinical study finds antidepressant may boost SMN
A preclinical study found that blocking the SMPD1 enzyme with available drugs such as the antidepressant clomipramine increases the levels of SMN
